{"log_id": 576307150934451061, "direction": 0, "words_result_num": 37, "words_result": [{"probability": {"variance": 0.006727, "average": 0.950309, "min": 0.582316}, "location": {"width": 1213, "top": 146, "height": 34, "left": 132}, "words": "应在降低剂后的大约2周:评估恢维莫司谷浓度(参见【用法用量】“推荐剂量”和“疗药物监测”)"}, {"probability": {"variance": 0.019669, "average": 0.924305, "min": 0.434654}, "location": {"width": 1229, "top": 201, "height": 38, "left": 130}, "words": "在用中效神制剂2-3大后,本品剂量应恢复到开始使用中效CYP3A4和线PP抑制剂之前的剂量水平"}, {"probability": {"variance": 0.027241, "average": 0.902299, "min": 0.377167}, "location": {"width": 1170, "top": 253, "height": 38, "left": 130}, "words": "在大约2周后再次评估依维桌司谷浓度(参见【用法用量】“推荐剂量”和“治疗药物鉴测”)"}, {"probability": {"variance": 0.038698, "average": 0.869266, "min": 0.40168}, "location": {"width": 1245, "top": 308, "height": 38, "left": 130}, "words": "避食用已知会制细胞色素P45和PgP活性的食物或营莽补宠剂(如西、西柚汁)。CYP3A强效浮"}, {"probability": {"variance": 0.004056, "average": 0.933447, "min": 0.869763}, "location": {"width": 57, "top": 365, "height": 32, "left": 82}, "words": "导剂"}, {"probability": {"variance": 0.017863, "average": 0.926788, "min": 0.466583}, "location": {"width": 1241, "top": 420, "height": 36, "left": 130}, "words": "如果有替代治疗可用,应避免同时使用强效CYP3A4诱导剂(如苯妥英、一马西平、利平、利有”"}, {"probability": {"variance": 0.032981, "average": 0.886266, "min": 0.354815}, "location": {"width": 1291, "top": 473, "height": 38, "left": 77}, "words": "利福喷汀、苯巴比妥)(秦见注意事项】“药物相互作用”及【药物互作用】“可降低依维莫司药浓"}, {"probability": {"variance": 0.009792, "average": 0.969733, "min": 0.483649}, "location": {"width": 678, "top": 528, "height": 34, "left": 77}, "words": "度的药物”)。对干需要使用强效CYP3A4诱导剂的患者"}, {"probability": {"variance": 0.011597, "average": 0.927733, "min": 0.594044}, "location": {"width": 621, "top": 580, "height": 36, "left": 130}, "words": "将本品剂加倍(参【用法用量】“排荐剂量”)"}, {"probability": {"variance": 0.022808, "average": 0.907773, "min": 0.484214}, "location": {"width": 1238, "top": 635, "height": 43, "left": 130}, "words": "应在剂量加倍后的大约2周,估依维莫司谷浓度,必要时调整剂号,使谷浓度维持在5~15ng/ml(参见"}, {"probability": {"variance": 0.012713, "average": 0.943312, "min": 0.565983}, "location": {"width": 585, "top": 690, "height": 36, "left": 139}, "words": "【用法用量】“推荐剂量”和“治疗药物监测”)"}, {"probability": {"variance": 0.015267, "average": 0.948953, "min": 0.368759}, "location": {"width": 1243, "top": 747, "height": 38, "left": 130}, "words": "在停用强诱导剂后,本品的剂量应恢复到开始使用强效CYP3A4诱导之的的剂量水平,并在大约2"}, {"probability": {"variance": 0.034368, "average": 0.897295, "min": 0.366025}, "location": {"width": 1033, "top": 800, "height": 36, "left": 130}, "words": "周后再次浮估依维司谷浓度(参见【用法用量】“荐剂量”和“治疗药物监”)"}, {"probability": {"variance": 0.021614, "average": 0.90656, "min": 0.457359}, "location": {"width": 998, "top": 854, "height": 41, "left": 128}, "words": "避免食用已知会诱导细色素P450活性的食物或营养补充酒(如圣约翰草金丝桃]"}, {"probability": {"variance": 3e-06, "average": 0.997672, "min": 0.994797}, "location": {"width": 155, "top": 957, "height": 34, "left": 61}, "words": "不良反应"}, {"probability": {"variance": 0.023746, "average": 0.90899, "min": 0.476944}, "location": {"width": 950, "top": 1014, "height": 34, "left": 125}, "words": "在说明书的另一章中更详细地讨论了下列严重不良反应(参见【注意事项】"}, {"probability": {"variance": 0.012585, "average": 0.960899, "min": 0.55928}, "location": {"width": 432, "top": 1069, "height": 34, "left": 194}, "words": "非感染性炎(参见【注意事项】"}, {"probability": {"variance": 0.002594, "average": 0.961058, "min": 0.864882}, "location": {"width": 320, "top": 1124, "height": 34, "left": 194}, "words": "感染(参见【注意事项"}, {"probability": {"variance": 0, "average": 0.775283, "min": 0.775283}, "location": {"width": 43, "top": 1133, "height": 45, "left": 1085}, "words": "2"}, {"probability": {"variance": 0.022014, "average": 0.928258, "min": 0.407304}, "location": {"width": 374, "top": 1179, "height": 32, "left": 194}, "words": "口腔溃疡(参见【注意事项)"}, {"probability": {"variance": 0, "average": 0.73382, "min": 0.73382}, "location": {"width": 70, "top": 1179, "height": 43, "left": 1014}, "words": "有"}, {"probability": {"variance": 0.016842, "average": 0.916138, "min": 0.551104}, "location": {"width": 404, "top": 1232, "height": 36, "left": 194}, "words": "肾功能衰竭(见【注意事项】)"}, {"probability": {"variance": 0.026125, "average": 0.916957, "min": 0.409948}, "location": {"width": 1241, "top": 1286, "height": 36, "left": 123}, "words": "客项临床试验的执行背量差异大,所以测到的不良反应发生率不能直接与其它试验中的发生率进"}, {"probability": {"variance": 0.007162, "average": 0.944457, "min": 0.715505}, "location": {"width": 683, "top": 1344, "height": 34, "left": 73}, "words": "行比较,并且可能小能反映出临庆实践中观察到的发生离"}, {"probability": {"variance": 0.004576, "average": 0.954227, "min": 0.78519}, "location": {"width": 420, "top": 1398, "height": 34, "left": 70}, "words": "晚期肾细胞癌患者的临床研究经验"}, {"probability": {"variance": 0.008384, "average": 0.948836, "min": 0.67035}, "location": {"width": 1238, "top": 1451, "height": 38, "left": 125}, "words": "以下资料指述了一项随机、对照试验的结果,使用过舒尼替尼利或索拉丰尼治疗的移性肾细胞癌患者"}, {"probability": {"variance": 0.010848, "average": 0.955894, "min": 0.438095}, "location": {"width": 1282, "top": 1506, "height": 34, "left": 70}, "words": "接受本品(n=274)和安慰剂(n=137)治疗。患者中位年龄为61岁范围为27-85岁:88%为高加素人"}, {"probability": {"variance": 0.013997, "average": 0.946663, "min": 0.391057}, "location": {"width": 1284, "top": 1561, "height": 36, "left": 75}, "words": "7%为男性。使用本品治疗患者的态研究治疗时中位数为141天(范压为1951天),应用安慰剂治疗"}, {"probability": {"variance": 0.015429, "average": 0.951623, "min": 0.427115}, "location": {"width": 608, "top": 1618, "height": 34, "left": 68}, "words": "意的治疗时间中位数为60天(范为21-25天"}, {"probability": {"variance": 0.022297, "average": 0.926882, "min": 0.414519}, "location": {"width": 1243, "top": 1673, "height": 34, "left": 121}, "words": "最常见的不良反应(发生率30%)为口腔炎、感,弱,乏力、咳嗽腹泻。最常见的3至4级小"}, {"probability": {"variance": 0.012678, "average": 0.937377, "min": 0.434377}, "location": {"width": 1296, "top": 1728, "height": 34, "left": 68}, "words": "良反应(发生率≥3%)为感染、呼吸困难、乏力、口腔炎、脱水、肺炎、腹痛和虚弱。最见的实验室异常"}, {"probability": {"variance": 0.024046, "average": 0.918286, "min": 0.445462}, "location": {"width": 1268, "top": 1783, "height": 34, "left": 96}, "words": "发生率≥5%)为贫血、高胆周醇瓶症、高甘油一酯血症、高血、淋巴细胞减少用凯酐升高。最常见的3"}, {"probability": {"variance": 0.015428, "average": 0.927796, "min": 0.444114}, "location": {"width": 1291, "top": 1835, "height": 36, "left": 68}, "words": "4级实验室异常(发牛率≥3%)为淋巴细胞减少、高血糖、贫血、低磷血症和高胆固醇血症。在依维莫"}, {"probability": {"variance": 0.023274, "average": 0.920458, "min": 0.353443}, "location": {"width": 1277, "top": 1892, "height": 34, "left": 66}, "words": "组观察到的死亡原因为急性呼吸衰竭(7%、感染(0.7%)和急性肾衰竭(04%):安慰剂组中没有死"}, {"probability": {"variance": 0.011749, "average": 0.96016, "min": 0.377298}, "location": {"width": 1291, "top": 1947, "height": 34, "left": 66}, "words": "本品和安剂组导水久性停药的治疗中不良件(不考虑因果关系)发生率分别为14%和3%。导致治疗中"}, {"probability": {"variance": 0.013815, "average": 0.944578, "min": 0.404653}, "location": {"width": 1264, "top": 2000, "height": 36, "left": 68}, "words": "断的最常见不良反应(考虑因果关系〕为肺炎和呼吸困难导致延迟治疗或减少剂量的最常见原因为感染"}, {"probability": {"variance": 0.020016, "average": 0.929062, "min": 0.380057}, "location": {"width": 1069, "top": 2057, "height": 36, "left": 68}, "words": "口腔炎和肺炎。在本品治疗过程需要进行医疗干预的最常见情况是感贫血和口腔炎"}], "language": 3}